SCHEMBL26127806

SCHEMBL26127806

CCOC(=O)CN1CCC2(CCN(c3ncc(C(F)(F)F)cn3)CC2)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ HPGD P15428 2/20 0.43
▸ PPARG P37231 1/20 0.43
▸ PPARD Q03181 1/20 0.43
▸ PPARA Q07869 1/20 0.43
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ USP2 O75604 3/20 0.40
▸ CYP2C9 P11712 2/20 0.40
▸ GRIN1 Q05586 2/20 0.39
▸ GRIN2B Q13224 2/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ POLB P06746 2/20 0.38
▸ GAA P10253 1/20 0.38
▸ RECQL P46063 1/20 0.38
▸ AOC3 Q16853 1/20 0.37
▸ CYP2D6 P10635 3/20 0.37
▸ CYP2C19 P33261 2/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ CYP3A4 P08684 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26125332 0.84 KCNH2 (0.46) SMN1; SMN2HPGDPPARGPPARDPPARA
SCHEMBL30286314 0.83 PARP1 (0.44) SMN1; SMN2PPARGPPARDPPARAUSP2
SCHEMBL13168167 0.81 CYP2C9 (0.39) SMN1; SMN2HPGDPPARGPPARDPPARA
SCHEMBL26126183 0.81 PPARG (0.41) SMN1; SMN2HPGDPPARGPPARDPPARA
SCHEMBL14671150 0.76 ELANE (0.40) SMN1; SMN2MEN1KMT2AL3MBTL1POLB
SCHEMBL26124703 0.75 HPGD (0.42) SMN1; SMN2HPGDPPARGPPARDPPARA
SCHEMBL9400930 0.74 SMN1; SMN2 (0.71) SMN1; SMN2HPGDPPARGPPARDPPARA
SCHEMBL26123468 0.74 GPR119 (0.48) SMN1; SMN2HPGDPPARGPPARDPPARA
SCHEMBL14996529 0.74 CYP3A4 (0.43) SMN1; SMN2PPARGPPARDPPARAMEN1
SCHEMBL14671148 0.73 KDM4E (0.39) SMN1; SMN2KMT2AUSP2L3MBTL1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240336596-A1 PARP7 INHIBITOR AND USE THEREOF NOVOSTAR PHARMACEUTICALS, LTD. (CN) 2024-10-10 — — US disclosed
EP-4338737-A1 PARP7 INHIBITOR AND USE THEREOF Novostar Pharmaceuticals, Ltd. (CN) 2024-03-20 — — EP disclosed
WO-2023185073-A1 PARP7 INHIBITOR AND USE THEREOF 诺沃斯达药业(上海)有限公司 2023-10-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240336596-A1 PARP7 INHIBITOR AND USE THEREOF PARP1, PARP3, PARP11 SMN1; SMN2 1592/4885HPGD 335/4885PPARG 1017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback